Murasawa Satoshi, Asahara Takayuki
Group of Vascular Regeneration, Institute of Biomedical Research and Innovation, Kobe, Japan.
Ther Adv Cardiovasc Dis. 2008 Oct;2(5):341-8. doi: 10.1177/1753944708096283.
Transplantation of endothelial progenitor cells (EPCs) are one of the promising strategies to recover the capillary flow in ischaemic diseases such as ischaemic heart disease and peripheral artery disease (PAD) in the leg. However, our previous and another group's works suggested the scarcity of the number of EPCs in peripheral blood might cause insufficient effect for the ischaemic diseases. There are several strategies to overcome this issue, such as (1) in vivo EPC expansion; (2) ex vivo EPC expansion; (3) local (not systemic) EPC injection; and (4) modification of EPC by gene transfer. Recent publications from our own and other groups have reported the possibility of cardiogenic potential of EPCs. We would like to focus on the strategies of EPC transplantation and cardiomyogenesis of EPCs in this review.
内皮祖细胞(EPCs)移植是恢复缺血性疾病(如缺血性心脏病和腿部外周动脉疾病(PAD))中毛细血管血流的一种有前景的策略。然而,我们之前以及另一组的研究表明,外周血中EPCs数量稀少可能导致对缺血性疾病的治疗效果不足。有几种策略可以克服这个问题,例如:(1)体内EPCs扩增;(2)体外EPCs扩增;(3)局部(而非全身)EPCs注射;以及(4)通过基因转移对EPCs进行修饰。我们自己以及其他团队最近发表的文章报道了EPCs具有心脏生成潜力的可能性。在这篇综述中,我们将重点关注EPCs移植策略以及EPCs的心肌生成。